2型糖尿病患者SLC22A1,SLC22A2基因多态性与二甲双胍胃肠道不良反应的关系

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (644 KB) RICH HTML
输出: BibTeX | EndNote (RIS)

摘要目的探讨2型糖尿病(T₂DM)患者SLC22A1 1222A＞G位点及SLC22A2 808G＞T位点基因多态性与二甲双胍胃肠道不良反应之间的关系。方法随机选取130例就诊于我院内分泌科初次接受二甲双胍治疗的T₂DM患者，从患者外周血白细胞中提取DNA，应用等位基因特异引物PCR反应(Allele-specific PCR，AS-PCR)及凝胶成像技术进行基因分型，分析1222A＞G及808G＞T位点多态性与二甲双胍胃肠道不良反应的关系。结果 SLC22A1 1222A＞G位点存在AA、AG、GG三种基因型，突变频率为64.62%，A等位基因与二甲双胍胃肠道不良反应的发生相关(P＜0.05);SLC22A2 808G＞T位点存在GG、GT、TT三种基因型，突变频率为11.15%，该位点不同基因型患者发生二甲双胍胃肠道不良反应的概率不存在统计学差异(P＝0.559);二甲双胍胃肠道反应阳性组患者年龄大于胃肠道反应阴性患者(P＝0.037);二甲双胍胃肠道反应阳性组患者收缩压高于胃肠道反应阴性患者(P＝0.017)。结论 T₂DM患者SLC22A1 1222A＞G基因多态性与二甲双胍胃肠道不良反应的发生相关，SLC22A2808G＞T基因多态性与二甲双胍胃肠道不良反应的发生无关;老龄及高收缩压可能是造成二甲双胍胃肠道不良反应的危险因素。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	符婷
	石建党
	匡霞
	王素莉

关键词 ：二甲双胍, SLC22A1, SLC22A2, 基因多态性, 胃肠道不良反应

Abstract：Objective To study the relationship between gene polymorphisms of 1222A＞G in SLC22A1 and 808G＞T in SLC22A2 with the gastrointestinal side-effects in metformin-treated type 2 diabetes patients.Methods One hundred and thirty type 2 diabetes patients treated with metformin at the first time were recruited.Genomic DNA samples were extracted from the patients’ leukocytes in the peripheral blood.The genotypes were determined by the allele-specific polymerase chain reaction(AS-PCR)and gel electrophoresismethod.Results Three genotypes of AA, AG, GG were found in SLC22A11222A＞G site and the mutation frequency was 64.62%.An allele of 1222A＞G was associated with the incidence of gastrointestinal side-effects of metformin(P＜0.05).Three genotypes of GG, GT, TT were found in SLC22A2 808G＞T site and the mutation frequency was 11.15%.The incidence of gastrointestinal side effects in metformin-treated type 2 diabetes patients with different genotypes had no significant differences(P＝0.559).The patients in metformin intolerance group were older than the patients in metformin tolerance group. The patients in metformin intolerance group had higher systolic blood pressure than the patients in metformin tolerance group.Conclusions SLC22A11222A＞G gene polymorphis was associated with the incidence of gastrointestinal side effects in metformin-treated type 2 diabetes patients, however SLC22A2 808G＞T is not.Older age and high systolic blood pressure may be the risk factors for metformin intolerance.

Key words： metformin SLC22A1 SLC22A2 gene polymorphisms gastrointestinal side-effects

收稿日期: 2015-11-11

ZTFLH:

R587.1

通讯作者: 王素莉,E-mail:wangslwsl@sina.com

作者简介: 符婷，硕士研究生，医师。

引用本文:

符婷，石建党，匡霞，王素莉. 2型糖尿病患者SLC22A1,SLC22A2基因多态性与二甲双胍胃肠道不良反应的关系[J]. 武警医学, 2016, 27(5): 456-459. FU Ting,SHI Jiandang,KUANG Xia,and WANG Suli. Association of genetic polymorphisms in SLC22A1 and SLC22A2 with intolerance to metformin in type 2 diabetes. Med. J. Chin. Peop. Armed Poli. Forc., 2016, 27(5): 456-459.

链接本文:

http://journal08.magtechjournal.com/Jwk_wjyx/CN/ 或 http://journal08.magtechjournal.com/Jwk_wjyx/CN/Y2016/V27/I5/456

[1]	Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists′ comprehensive diabetes management algorithm 2013 consensus statement-executive summary[J]. Endocr Pract, 2013,19(3):536-557.
[2]	Ma J, Liu LY, Wu PH, et al. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China[J]. J Diabetes Res, 2014,2014:294017.
[3]	Wang H, Ni Y, Yang S, et al. The effects of gliclazide, metformin, and acarbose on body composition in patients with newly diagnosed type 2 diabetes mellitus[J]. Curr Ther Res Clin Exp, 2013,75:88-92.
[4]	Sin HY, Kim JY, Jung KH. Total cholesterol, high density lipoprotein and triglyceride for cardiovascular disease in elderly patients treated with metformin[J]. Arch Pharm Res, 2011,34(1):99-107.
[5]	Fruci B, Giuliano S, Mazza A, et al. Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment[J]. Int J Mol Sci, 2013,14(11):22933-22966.
[6]	Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility[J]. Cochrane Database Syst Rev, 2010,(1):CD003053.
[7]	Bouchoucha M, Uzzan B, Cohen R. Metformin and digestive disorders[J]. Diabetes Metab, 2011,37(2):90-96.
[8]	Kimura N, Masuda S, Tanihara Y, et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1[J]. Drug Metab Pharmacokinet, 2005,20(5):379-386.
[9]	Chen Y, Li S, Brown C, et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin[J]. Pharmacogenet Genomics, 2009,19(7):497-504.
[10]	Leabman MK, Huang CC, Kawamoto M, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function[J]. Pharmacogenetics, 2002,12(5):395-405.
[11]	Tarasova L, Kalnina I, Geldnere K, et al. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients[J]. Pharmacogenet Genomics, 2012,22(9):659-666.
[12]	Dujic T, Zhou K, Donnelly LA, et al. Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study[J]. Diabetes, 2015,64(5):1786-1793.
[13]	Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update[J]. Ann Intern Med, 2002,137(1):25-33.
[14]	Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics[J]. Science, 1999,286(5439):487-491.
[15]	Ieiri I, Takane H, Hirota T, et al. Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy[J]. Expert Opin Drug Metab Toxicol, 2006,2(5):651-674.
[16]	Li Q, Liu F, Zheng TS, et al. SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin[J]. Acta Pharmacol Sin, 2010,31(2):184-190.
[17]	Wang ZJ, Yin OQ, Tomlinson B, et al. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine[J]. Pharmacogenet Genomics, 2008,18(7):637-645.
[18]	Kang HJ, Song IS, Shin HJ, et al. Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population[J]. Drug Metab Dispos, 2007,35(4):667-675.
[19]	Tzvetkov MV, Vormfelde SV, Balen D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin[J]. Clin Pharmacol Ther, 2009,86(3):299-306.
[20]	Song IS, Shin HJ, Shim EJ, et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin[J]. Clin Pharmacol Ther, 2008,84(5):559-562.
[21]	Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine[J]. Drug Metab Dispos, 2007,35(10):1956-1962.